According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit
psoriasis, which is considered to be an autoimmune disease.
[Bridgman2018 🕮 ] A 60-year-old white woman with a history of psoriasis vulgaris covering 10% of
her body surface area was treated with 4.5mg/day LDN.
The patient's psoriatic lesions were significantly improved at 3 months, and after 6 months of treatment the affected
body surface area had shrunk to 1%.
[Muller2018 🕮 ] A 75-year-old white male patient with guttate psoriasis was successfully treated with oral LDN.
The only adverse effect was dry skin near the lesions on the patient's arms and legs.
[Monasterio2019 🕮 ] reports treatment of a patient with erythrodermic psoriasis flare-up using 4.5mg/day of LDN. The patient showed significant improvement in her flare-up and psoriasis remission after three months of 4.5mg/day of LDN.
Dr. Weyrich has been trained to use Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of Psoriasis
with LDN.
Please see What is Low Dose Naltrexone?
for more information.
[McCulley2018, pp 28, 33, 35, 62, 89] reports that psoriasis may be a
TH1- and TH17-dominant, localized,
autoimmune disorder, and proposes an approach to treating this disease, which should be
supervised by a properly trained medical professional.
Dr. Weyrich has considerable interest in this topic, but has
not treated any cases of psoriasis
with Immune System Balancing.
Please see What is Immune System Balancing?
for more information.